Beacon Investment Advisory Services Inc. Sells 4,535 Shares of Pfizer Inc. $PFE

Beacon Investment Advisory Services Inc. reduced its position in shares of Pfizer Inc. (NYSE:PFE) by 15.3% in the second quarter, according to its most recent filing with the SEC. The fund owned 25,192 shares of the biopharmaceutical company’s stock after selling 4,535 shares during the quarter. Beacon Investment Advisory Services Inc.’s holdings in Pfizer were worth $611,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Regatta Capital Group LLC raised its stake in Pfizer by 44.4% during the second quarter. Regatta Capital Group LLC now owns 20,928 shares of the biopharmaceutical company’s stock valued at $507,000 after purchasing an additional 6,431 shares in the last quarter. Signet Financial Management LLC increased its holdings in shares of Pfizer by 9.3% in the 2nd quarter. Signet Financial Management LLC now owns 9,040 shares of the biopharmaceutical company’s stock worth $219,000 after buying an additional 767 shares during the last quarter. Wealth Effects LLC raised its position in shares of Pfizer by 8.5% during the 2nd quarter. Wealth Effects LLC now owns 71,133 shares of the biopharmaceutical company’s stock valued at $1,724,000 after buying an additional 5,572 shares in the last quarter. TD Private Client Wealth LLC lifted its holdings in shares of Pfizer by 19.9% in the 2nd quarter. TD Private Client Wealth LLC now owns 153,109 shares of the biopharmaceutical company’s stock valued at $3,711,000 after acquiring an additional 25,456 shares during the last quarter. Finally, Foster Victor Wealth Advisors LLC grew its position in Pfizer by 7.7% in the second quarter. Foster Victor Wealth Advisors LLC now owns 644,591 shares of the biopharmaceutical company’s stock worth $16,476,000 after acquiring an additional 46,116 shares in the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on PFE. Morgan Stanley upped their price objective on Pfizer from $32.00 to $33.00 and gave the company an “equal weight” rating in a research report on Wednesday, August 6th. Citigroup increased their price target on Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a report on Wednesday, August 6th. Bank of America lifted their price objective on shares of Pfizer from $27.00 to $28.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 6th. Wall Street Zen upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a research report on Saturday, September 20th. Finally, Berenberg Bank lowered their target price on shares of Pfizer from $28.00 to $25.00 and set a “hold” rating for the company in a report on Thursday, May 29th. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Pfizer presently has a consensus rating of “Hold” and an average price target of $28.12.

Pfizer Trading Down 2.0%

PFE stock opened at $23.61 on Friday. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $30.43. The firm’s 50-day moving average is $24.57 and its 200 day moving average is $24.16. The company has a market capitalization of $134.25 billion, a PE ratio of 12.56, a P/E/G ratio of 0.78 and a beta of 0.55. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping analysts’ consensus estimates of $0.58 by $0.20. The business had revenue of $14.65 billion for the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The company’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, research analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.